Depicting brighter possibilities for treating blindness

Sci Transl Med. 2019 May 29;11(494):eaax2324. doi: 10.1126/scitranslmed.aax2324.

José-Alain Sahel^{1

2

3

4}, Jean Bennett⁵, Botond Roska^{6

7

8}

¹ Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. sahelja@upmc.edu jebennet@pennmedicine.upenn.edu botond.roska@iob.ch.
² Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012 Paris, France.
³ CHNO des Quinze-Vingts, INSERM-DGOS CIC 1423, 28 rue de Charenton, F-75012 Paris, France.
⁴ Fondation Ophtalmologique Rothschild, 29 rue Manin, F-75019 Paris, France.
⁵ Center for Advanced Retinal and Ocular Therapeutics, Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. sahelja@upmc.edu jebennet@pennmedicine.upenn.edu botond.roska@iob.ch.
⁶ Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland. sahelja@upmc.edu jebennet@pennmedicine.upenn.edu botond.roska@iob.ch.
⁷ University of Basel, Basel, Switzerland.
⁸ Friedrich Miescher Institute, Basel, Switzerland.

Abstract

Advances in preclinical research are now being translated into innovative clinical solutions for blindness.